PDL BioPharma (NASDAQ:PDLI) says it expects Q3 revenue of $83M (-3% Y/Y), guidance below analyst estimates of $87.7M. The firm expects reduced royalty revenue from Avastin to only be partially offset by an increase in royalties from Herceptin, Lucenits and Tysabi. Shares -1.2% premarket.